ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2010
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.PharmacoEconomics · 2015Pooled it
- Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.BMC psychiatry · 2012Pooled it
- A randomised controlled trial of adjunctive yoga and adjunctive physical exercise training for cognitive dysfunction in schizophrenia.Acta neuropsychiatrica · 2017Trial
- Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.Schizophrenia research · 2012Trial
- Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.Schizophrenia research · 2011Trial
- The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.Neuropsychiatric disease and treatment · 2023Review
- Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.Clinical drug investigation · 2021Article
- Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.Clinical drug investigation · 2020Article
- Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital.Neurology and therapy · 2019Article
- Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Review
- The Cost of Relapse in Schizophrenia.PharmacoEconomics · 2017Review
- Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Clinical drug investigation · 2017Article
- Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.PloS one · 2017Article
- Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.Neuropsychiatric disease and treatment · 2015Article
- Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Neuropsychiatric disease and treatment · 2015Article
- Article
- Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.Schizophrenia research and treatment · 2012Article
- Clinical utility of the risperidone formulations in the management of schizophrenia.Neuropsychiatric disease and treatment · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo estimate changes in resource usage, hospitalization rates, and costs in actual practice in Sweden for schizophrenia patients after switching to long-acting injectable risperidone (Risperdal Consta).
methodsA retrospective chart review within-subject mirror-image study using actual practice chart review data was used to compare annual hospital bed-days and annual hospital episodes for adults with schizophrenia or schizoaffective disorder before and after switching to Risperdal Consta in the period 1 January 2003 to 30 June 2005. Secondary endpoints included mean length of hospital stay per episode, the cost of hospitalization, and the cost of antipsychotic treatment. The base case analytical approach allocated all hospital episodes overlapping the switch date entirely to pre-switch treatment. In order to investigate the impact of inpatient care ongoing at the time of the switch, the change in bed-days per year was also estimated using an alternative analytical approach inspired by economic modelling.
resultsOne-hundred sixty-four patients were enrolled at nine geographically diverse sites. The switch to Risperdal Consta was associated with a significant reduction in mean annual days in hospital from 39 to 21 days per year (45%), which was linked to a significant reduction in the number of hospitalizations from 0.86 to 0.63 per year (27%). The alternative "modelling-inspired" estimate of the reduction in mean annual days in hospital was also 27%.
conclusionA naturalistic mirror-image study found that switching to long-acting injectable risperidone led to sizeable reductions in inpatient resource use. These results coincide with the findings of other international studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.